Stockscreener 앱 받기
0.231
1.28%
-0.003
전일 마감가:
$0.234
열려 있는:
$0.217
하루 거래량:
1.32M
Relative Volume:
1.18
시가총액:
$3.49M
수익:
-
순이익/손실:
$-58.92M
주가수익비율:
-0.00504
EPS:
-45.8429
순현금흐름:
$-401.10K
1주 성능:
+14.41%
1개월 성능:
-49.02%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.2056
$0.231
1주일 범위
$0.1629
$0.239
52주 변동 폭
$0.1555
$9.36
Propanc Biopharma Inc Stock (PPCB) Company Profile
명칭
Propanc Biopharma Inc
전화
61-03-9882-0780
주소
302/6 BUTLER STREET, CAMBERWELL, VICTORIA
Compare PPCB vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PPCB
Propanc Biopharma Inc
|
2.87 | 244.39K | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
2.22 | 3.25B | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
8.69 | 536.01M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.32 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
2.8999 | 277.51M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DWLD
Davis Select Worldwide ETF
|
46.01 | 0 | 0 | 0 | 0 | 0.00 |
Propanc Biopharma Inc 주식(PPCB)의 최신 뉴스
Certain Warrants of Propanc Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 10-FEB-2026. - marketscreener.com
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market - The Manila Times
Lab tests: Propanc’s PRP slowed tumor growth 85%, human trial planned - Stock Titan
Propanc Biopharma files fourth patent application in two months By Investing.com - Investing.com Australia
Propanc Biopharma files fourth patent application in two months - Investing.com
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations - marketscreener.com
Propanc Biopharma Accelerates IP Momentum: Files Fourth - GlobeNewswire
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two MonthsStrengthening Global Protection for Breakthrough Proenzyme Formulations - The Manila Times
Propanc Biopharma files new patent for synthetic cancer treatment - Investing.com
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia - The Manila Times
Propanc Biopharma, Inc. Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia - marketscreener.com
Propanc Biopharma files new patent for synthetic cancer treatment By Investing.com - Investing.com Nigeria
Propanc Biopharma advances pancreatic cancer treatment toward clinical trials By Investing.com - Investing.com Nigeria
Propanc Biopharma advances pancreatic cancer treatment toward clinical trials - Investing.com
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer - The Manila Times
Two pancreatic proenzymes could offer new options for deadly cancer - Stock Titan
Propanc Biopharma plans phase 1b trial for cancer treatment PRP By Investing.com - Investing.com Canada
Propanc Biopharma plans phase 1b trial for cancer treatment PRP - Investing.com
Propanc Biopharma Provides Shareholder Update - The Manila Times
Cancer-focused biopharma Propanc plans 2026 human trial, fibrosis work - Stock Titan
Contrasting GRAIL (NASDAQ:GRAL) and Propanc Biopharma (OTCMKTS:PPCB) - Defense World
Propanc Biopharma Receives Nasdaq Minimum Bid Price Notice - TipRanks
Propanc Biopharma Received Notice of Noncompliance - TradingView — Track All Markets
Propanc Biopharma (NASDAQ: PPCB) details 2M-share Series C resale - Stock Titan
Propanc Biopharma files prospectus for resale of 2 million shares by selling stockholderSEC filing - marketscreener.com
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology - The Globe and Mail
Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal - The Manila Times
Study tests enzyme mix that may disrupt deadly pancreatic tumors' support cells - Stock Titan
Propanc Biopharma, Inc. (PPCB) Stock Forecast & Price Prediction 2025–2030 - CoinCodex
Propanc Biopharma Shares Gain After Seeking Patent Protection for New Cancer and Fibrosis Treatments - MSN
Propanc Biopharma Inc. (PPCB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Propanc Biopharma, Inc. (PPCB) -6.3% in After-hours: Shares Slide Amid Investigation Announcement - Stocks Telegraph
Propanc Biopharma Investigates 'Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs - The Manila Times
Propanc Biopharma (Nasdaq: PPCB) targets fibrosis, cancer via PRP EMT research - Stock Titan
Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs - FinancialContent
Views of Wall Street’s Leading Experts on Propanc Biopharma Inc - setenews.com
Propanc Biopharma (PPCB) Stock Analysis Report | Financials & Insights - Benzinga
Propanc Biopharma files patents for resistant cancer and fibrosis treatments By Investing.com - Investing.com Australia
Propanc Biopharma stock rises after filing for patents to treat resistant cancer By Investing.com - Investing.com South Africa
Propanc Biopharma stock rises after filing for patents to treat resistant cancer - Investing.com Australia
Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis - The Manila Times
Propanc Biopharma files patents for resistant cancer and fibrosis treatments - Investing.com
Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant ... - Enidnews.com
Propanc Biopharma (Nasdaq: PPCB) moves to patent PRP use in fibrosis ahead of 2026 Phase 1b trial - Stock Titan
Propanc Biopharma secures up to $100 million private placement - MSN
Propanc Biopharma Inc Share PricePPCB, RNS News, Articles, Quotes, & Charts (OTCMKTS:PPCB) - Proactive financial news
Australian firm launches crypto treasury for the future of cancer drug - Proactive financial news
Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results - The Manila Times
Propanc Biopharma (Nasdaq: PPCB) Raises $4M, Lists on Nasdaq, Sets $100M Facility - Stock Titan
Propanc Biopharma, Inc. SEC 10-Q Report - TradingView
Propanc Biopharma Secures $1M Through Stock Sale - MSN
Propanc Biopharma Inc (PPCB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):